Trevi Therapeutics, Inc.
Financials
Valuation Metrics
Trevi Therapeutics, Inc.'s Market Cap is $1.94B. At end of 2025 it was $1.82B. Ranked #1999 of 3,116 in US market (top 64%), #756 of 1,472 on NASDAQ (top 51%), #141 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 53%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.94B | US#1,999/3,116 Sec#141/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-51M | US—/3,116 Sec—/265 |
| Total Assets | $331M | US#2,883/3,116 Sec#199/265 |
| Net Assets | $322M | US#2,478/3,116 Sec#153/265 |
| Employees | 34 | US#2,728/3,116 Sec#215/265 |
| Value | ||
| P/B | 6.02x | US#2,351/3,116 Sec#159/265 |
| FCF Yield | -2.04% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -15.90% | US#2,431/3,116 Sec#93/265 |
| ROA | -15.46% | US#2,744/3,116 Sec#122/265 |
| Financial Health | ||
| Debt Ratio | 2.80% | US#25/3,116 Sec#6/265 |
| Total Debt | $605000.00 | US#2,981/3,116 Sec#249/265 |
| FCF | $-39M | US#2,496/3,116 Sec#108/265 |
| Cash | $54M | US#2,545/3,116 Sec#220/265 |
| Current Ratio | 37.28x | US#67/3,116 Sec#7/265 |
| Performance | ||
| 1Y Return | 16.90% | US#895/3,116 Sec#96/265 |
| 1M Return | -2.01% | US#2,241/3,116 Sec#161/265 |
| From 52W High | -32.59% | US#2,072/3,116 Sec#138/265 |
| 1Y MDD | -39.08% | US#1,891/3,116 Sec#115/265 |
| Trading | ||
| Volume | 1,374,796 shares | US#1,239/3,116 Sec#120/265 |
| Trading Value | $19M | US#1,945/3,116 Sec#151/265 |
| Per Share | ||
| EPS | $-0.36 | US—/3,116 Sec—/265 |
| BPS | $2.26 | US#2,547/3,116 Sec#170/265 |
Company Info
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.